Five Prime Thera Cmn (FPRX) 50.69 $FPRX Five Prime

New Post Public Reply Private Reply Replies (0) Message Board

Jul 31, 2016 at 11:11 PM

Five Prime Thera Cmn (FPRX) 50.69 $FPRX

Five Prime Therapeutics Presents Updated Data from Phase 1 trial of Single-Agent FPA144 at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 8:25AM CDT
-- Initial data show a 33% confirmed objective response rate, 77% disease control rate, and 12-week progression free survival of 67% in 9 FGFR2b+ gastric cancer patients available for analysis
FPRX: 50.69 (+1.47)

Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Sat Jun 04, 8:24AM CDT
-- Objective response rate of 39% and disease control rate of 100% in patients at or below the maximum tolerated dose level; progression free survival of 6.8 months, though data are still maturing
FPRX: 50.69 (+1.47)

Five Prime Therapeutics to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 8:30AM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Robert Sikorski, MD, PhD, Chief Medical Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016, at 2:30 PM Eastern Daylight Time.
FPRX: 50.69 (+1.47)

Five Prime Therapeutics Appoints Dr. Robert Sikorski as Chief Medical Officer
GlobeNewswire - Wed Jun 01, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Robert Sikorski, M.D., Ph.D., to chief medical officer. In this role, he will oversee all clinical development (including clinical operations, pharmacovigilance, pharmacokinetics and biostatistics) and regulatory affairs, and will play a leading role in advancing Five Prime's immuno-oncology portfolio.
FPRX: 50.69 (+1.47)

How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 7.39 (+0.42), RDUS: 47.12 (+1.32), ARWR: 5.96 (-0.02), FPRX: 50.69 (+1.47)

Five Prime Therapeutics Announces Updated Clinical Data on FPA144 and FP-1039 to be Presented during 2016 ASCO Annual Meeting
GlobeNewswire - Wed May 18, 4:00PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that updated data from the ongoing clinical trials of FPA144 and FP-1039 will be presented during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3-6, 2016, in Chicago. The presentation abstracts are now available online at the meeting website: https://iplanner.asco.org/am2016/#/. Information contained in the abstracts was as of the time of submission in February 2016. Five Prime intends to announce more detailed results at the time of the presentations at the ASCO Annual Meeting.
FPRX: 50.69 (+1.47)

Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis (PVNS)
GlobeNewswire - Thu May 12, 8:00AM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the advancement of FPA008 into the Phase 2 dose expansion portion of the ongoing Phase 1/2 trial in PVNS.
FPRX: 50.69 (+1.47)

Five Prime Therapeutics posts 1Q loss
Automated Insights - Thu May 05, 6:12PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Thursday reported a loss of $13 million in its first quarter.
FPRX: 50.69 (+1.47)

Five Prime Therapeutics to Announce First Quarter 2016 Financial Results and Host Conference Call on May 5
GlobeNewswire - Thu Apr 21, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2016 financial results on Thursday, May 5, 2016, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, May 5, 2016, at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 50.69 (+1.47)

Top 4 Sales Growth Stocks
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 12:25PM CDT
Sales growth is an important indicator of a company's health and ability to sustain its business.
GILD: 79.47 (-1.77), TROW: 70.69 (+0.25), RMD: 68.88 (+3.18), FPRX: 50.69 (+1.47)

Five Prime Therapeutics Announces New Pre-Clinical Data on FPA144 Presented at the 2016 AACR Annual Meeting
GlobeNewswire - Mon Apr 18, 8:00AM CDT
-- Engineering of FPA144 for ADCC drives both innate and adaptive responses
FPRX: 50.69 (+1.47)

Looking for a Top Momentum Stock? 3 Reasons Why Five Prime Therapeutics (FPRX) is a Great Choice
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:28AM CDT
Five Prime Therapeutics is a great momentum stock and has been witnessing positive activity in the earnings estimate revision front as well
FPRX: 50.69 (+1.47)

Five Prime Therapeutics Announces FPA144 Will Be Featured During a Special Session at the 2016 AACR Annual Meeting
GlobeNewswire - Mon Apr 11, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that it will present the FPA144 program during a special session at the 2016 American Association for Cancer Research (AACR) Annual Meeting, being held April 16-20 in New Orleans.
FPRX: 50.69 (+1.47)

Can the Rally in Five Prime Therapeutics (FPRX) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:27AM CDT
Five Prime Therapeutics Inc (FPRX) has been on the move lately as the stock has risen by 38.2% in the past four weeks, and it is currently trading well above its 20-Day SMA
FPRX: 50.69 (+1.47)

Five Prime Therapeutics to Present at the 2016 Jefferies Immuno-Oncology Summit
GlobeNewswire - Fri Apr 01, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., Founder, Chief Executive Officer and Chairman of the Board, will present at the 2016 Jefferies Immuno-Oncology Summit on Friday, April 8, 2016, at 11:00 A.M. Eastern Daylight Time.
FPRX: 50.69 (+1.47)

Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:25AM CDT
Five Prime Therapeutics, Inc. (FPRX) saw its shares rise just over 5% on the day.
AMAG: 26.53 (-0.06), FPRX: 50.69 (+1.47)

Five Prime Therapeutics Announces Changes to Board of Directors
GlobeNewswire - Wed Mar 16, 8:00AM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced changes to its Board of Directors. Mr. Brian Atwood, who has served as a board member since 2002 when he lead the initial round of investment in Five Prime on behalf of Versant Ventures, and as Chairman of the Board since January 2012, has retired from the board. He will now focus on his existing responsibilities to Versant Ventures, and the start-up of a new company he recently co-founded where he is president and chief executive officer.
FPRX: 50.69 (+1.47)

Five Prime Therapeutics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Fri Mar 11, 3:05PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2016 at 10:45 AM Eastern Daylight Time.
FPRX: 50.69 (+1.47)

Five Prime Therapeutics posts 4Q profit
Automated Insights - Thu Mar 10, 6:11PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Thursday reported fourth-quarter net income of $296.1 million, after reporting a loss in the same period a year earlier.
FPRX: 50.69 (+1.47)

Five Prime Announces Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Thu Mar 10, 3:05PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2015.
FPRX: 50.69 (+1.47)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....